Study of Two Fractions versus Three Fractions of High Dose Rate Brachytherapy in Locally Advanced Carcinoma of Uterine Cervix after Pelvic Concurrent Chemoradiotherapy

Israt Jahan, MBBS, MD1, Abdul Bari, MBBS, MPhil2, Prof Sarwar Alam, MBBS, DMRT3, Niaz Mostafa, MBBS, FCPS, MRCP4

1,2Department of Radiation Oncology CMH, Dhaka, Bangladesh
3Department of Onology Bangabandhu Sheikh Mujib Medical University BSMMU, Dhaka, Bangladesh

DOI: 10.36347/sjmcr.2020.v08i12.013 | Received: 30.11.2020 | Accepted: 14.12.2020 | Published: 26.12.2020

*Corresponding author: Israt Jahan

Abstract

Uterine cervical cancer is the commonest form of gynecologic malignancy in Bangladesh and South east Asia. The aim of this study was to compare the treatment outcome and complications following treatment with 9 Gy (gray) in two fractions of intracavitery radiotherapy (ICRT) following external beam radiotherapy (EBRT) with 7 Gy in three fractions of ICRT. A prospective randomized study carried out in different tertiary hospitals of Bangladesh during the period of 2015 to 2016 with a number of 61 patients evaluated, all patients received EBRT 50 Gy in 25 fraction of 2Gy per fraction over a period of 5 weeks and inj. Cisplatin 40 mg/m² weekly. Then ICRT weekly two fractions with 9 Gy per fraction in arm A and three fractions of 7 Gy to arm B was delivered. At 3 years follow up, complete remission was 77% and 73% respectively for arm A and arm B. The overall complete response was 75%. The common toxicities associated with treatment were bladder and rectal toxicities, skin reaction and hematologic complications which were managed well. During follow up after 3 years, there was no grade 3 or 4 toxicities and rectal and bladder toxicities were similar in both arms. This study showed that after standard EBRT total dose of 18 Gy ICRT in two fractions of 9 Gy over 2 weeks is equally effective in local control with acceptable toxicities in comparison with a total dose of 21 Gy in three fractions of 7 Gy ICRT.  

Key words: Brachytherapy, Gray, Carcinoma cervix, Treatment response, Toxicity.
Treatment duration of cervical carcinoma with radiotherapy (EBRT and ICRT) should be as short as possible (within 8 weeks), and any planned or unplanned interruptions or delays should be avoided. Overall treatment time should not exceed 56 days including brachytherapy and should ideally be 49 days or less. Lower pelvic tumor control and survival rates are observed in invasive carcinoma of the uterine cervix when the overall treatment time in a course of irradiation is prolonged [6].

Bangladesh is a developing country with a dense population. In Bangladesh 80% of carcinoma of uterine cervix presents at a fairly advanced stage with a high mortality rate. We have a variety of problems in managing cervical cancer including patient load, which is very high due to inadequate number of radiotherapy centre with lesser number of brachytherapy machine. So, if decreasing the insertion of HDR brachytherapy from 3 to 2 fractions gives similar result, then it will help patients by reducing treatment cost and decreasing repeated attendance in hospital, as well as reduction in patient load in radiotherapy centres to some extent and more patients will get chance of treatment.

So, the objective of this study was to observe and compare the local control of disease and complications following treatment of locally advanced carcinoma cervix with two fractions of HDR brachytherapy after standard concurrent chemoradiation and compare it with brachytherapy of three fractions.

MATERIALS AND METHODS

It was a prospective randomized study and conducted in Department of Oncology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Shahbag, Dhaka and Department of Radiation Oncology, National Institute of Cancer Research and Hospital (NICRH), Mohakhali, Dhaka, Bangladesh. The duration was three year from December 2015 to December 2018.

A total 70 patients with clinically diagnosed and histologically proven locally advanced squamous cell carcinoma of the uterine cervix (Stage IIB- Stage IVA) were selected as sample and finally total 61 patients who met the study criteria were evaluated and analyzed. The aim of this study was to see the local control of different fractionation of brachytherapy as the primary outcome and secondary outcome was to compare the toxicities.

Ethical approval was taken from the institutional review board (IRB) of BSMMU (No. BSMMU/2015/13577 dated 14-11-2015), informed consent was taken from each patient before enrolling in the study.

For radiotherapy the target volume was whole pelvis encompassing the extent of primary tumor and the pelvic lymph nodes. During EBRT whole pelvis was treated with 2 Gy per fraction, 5 days in a week with a total dose of 50 Gy for 5 weeks in a Cobalt 60 teletherapy machine with SSD of 100 cm, Inj. cisplatin 40 mg/m$^2$ was given weekly to the patients on days 1, 8, 15, 22 and 29. After EBRT, all the patients of both arms were treated with HDR ICRT. A dose of 9 Gy per fraction, 2 fractions in 2 weeks for arm A and 7 Gy per fraction, a total of 3 fractions over 3 weeks for arm B to the point-A were given. A total ICRT dose of 18 Gy and 21 Gy were delivered for arm A and B respectively. The bladder and rectal dose was calculated in bladder and rectal point.

RECIST (response evaluation criteria for solid tumors) criteria was followed to assess the treatment response. For toxicity assessment, ‘Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) 1995’criteria was used. SPSS software (version 20) was used for data analysis. Chi square test was used for comparison of demographic variables and qualitative data.

OBSERVATIONS AND RESULTS

Over the study period, 33 patients received two fractions of 9 Gy brachytherapy after EBRT. After the exclusion of two patients who were lost to follow up, 31 patients were included in the present analysis. Patients included in the study group was propensity-matched 1:1 with a control group of same number of patients who completed EBRT with same dose followed by ICRT of 7 Gy in three fractions.

Patients with locally advanced carcinoma of uterine cervix were enrolled in this study and demographic and baseline characteristics were comparable in both groups (shown in table 1),
Most of the patients were diagnosed as stage IIB disease in both arms, 18(58%) and 16(53.0%) patients in Arm A and B respectively. 13 patients (41%) in Arm-A & 13 patients (43%) in Arm-B were in Stage IIB & there was only 1 patient from stage IVA in Arm-B.

At 1st follow up 6 weeks after completion of treatment, complete response was observed in 16 (51%) of Arm-A and 13 (43%) of Arm-B patients. There was no statistically significant difference in complete and partial response between two arms on the basis of staging (p>0.05). Then response evaluation was done at 2nd follow up which was at 12th week after completion of treatment. Response was similar like 1st follow up and there was no progression of disease.

At follow up of 6 month (24 weeks) it was observed that 90% of patients had complete response in Arm A. In Arm B 86% had complete response. The overall complete remission was 88%. Statistical analysis revealed there was no significant difference in both arms. Then follow up was done at 3 monthly intervals and clinical and radiologic analysis was done upto 3 years.

Finally at 3 years follow up, complete response was 75% in both arms with 77% for arm A and 73% for arm B and p value was not significant 0.913144.

The frequencies of acute toxicities related to treatment were a little bit higher in Arm A than that of Arm B but all the toxicities were managed well by conservative treatment. There was no grade III or higher toxicities, treatment discontinuation or hospitalization for toxicity management was not needed during treatment and follow-up period. Most of the patients suffered from rectal and blader toxicities in both arms.

| Characteristic                          | Arm A (n=31) | Arm B (n=30) |
|----------------------------------------|--------------|--------------|
| Age at diagnosis                       |              |              |
| 31 to 60                               | 26(83)       | 25(83)       |
| Above 60                               | 5(16)        | 5(16)        |
| Early age of marriage (<16 year)       | 87%          | 83%          |
| Lower Economic condition               | 60%          | 63%          |
| Grand multiparous                      | 62%          | 56%          |
| Sign and symptom                       |              |              |
| Post Coital Bleeding                   | 25 (80)      | 24 (80.0)    |
| Intermenstrual bleeding /Postmenopausal bleeding | 20 (64)    | 18 (60.0)    |
| Excessive per vaginal Discharge        | 27(87)       | 28(93.3)     |
| Pelvic Pain                            | 10 (32)      | 12 (40.0)    |
| Dysuria                                | 6 (19)       | 7 (23.33)    |
| Rectal Pain                            | 0(0)         | 0(0)         |
| Loss Of Appetite                       | 19 (61)      | 18 (60.0)    |
| Anemia                                 | 22 (71)      | 23 (76.7)    |

Table-II: Distribution of the patients according to treatment response at 6 month

| Response                   | Arm A (total=31) | Arm B (total =30) | Total |
|----------------------------|------------------|-------------------|-------|
| Complete response          | 27(87)           | 26(86)            | 53(87)|
| Partial response           | 4(13)            | 4(13)             | 8(13) |
| Progressive disease        | 0                | 0                 | 0     |

Table-III: Distribution of the patients according to treatment response at 3 years

| Response  | Arm A (total=31) | Arm B (total =30) | Total | P value |
|-----------|------------------|-------------------|-------|---------|
| Disease free | 24(77)           | 22(73)            | 46(75)| 0.91    |
| Local failure | 4                | 5                 | 9 (14)|         |
| Distant failure | 3                | 3                 | 6 (9) |         |
### Table-IV: Distribution of patients according to toxicity (during treatment)

| Variables            | Group (Total=61) | p value |
|----------------------|------------------|---------|
|                      | Arm-A [n (%)]    | Arm-B [n (%)] |       |
| **Skin Reaction**    |                  |          |       |
| Grade 1              | 10 (33.33)       | 9 (30)   | 0.967 |
| Grade 2              | 8 (26.66)        | 7 (23.33)|       |
| **Vaginal mucositis**|                  |          |       |
| Grade 1              | 8 (26.66)        | 6 (20)   | 0.746 |
| Grade 2              | 4 (13.33)        | 4 (13.33)|       |
| **Bladder toxicity** |                  |          |       |
| Grade-1              | 12 (40.0)        | 10 (33.3)| 0.878 |
| Grade 2              | 8 (26.66)        | 6 (20)   |       |
| **Rectal toxicity**  |                  |          |       |
| Grade-1              | 9 (30)           | 10 (33.3)| 0.370 |
| Grade 2              | 10(33.33)        | 6 (20)   |       |
| **Haematologic toxicities** |        |          |       |
| Grade 1              | 10 (3)           | 11 (37)  | 0.473 |
| Grade 2              | 5 (17)           | 3 (10)   |       |

During follow up at 3 years after completion of treatment 3 patients in arm A and 2 patients in arm B developed grade II bladder toxicities and only 5 patients in arm A and 3 patients in arm B developed rectal grade II toxicities. The late bladder and rectal toxicity was higher in arm A than arm B but it was not statistically significant (p value 0.2899).

### Table-V: Distribution of patients according to late toxicities (at 3 years)

| Toxicity (grade 2) | Arm A (total=31) n(%) | Arm B (total=30) n(%) | p value |
|--------------------|------------------------|------------------------|---------|
| Bladder            | 3(9%)                  | 2(6.66%)               | 0.928   |
| Rectal             | 5(16%)                 | 3(10)                  |         |

**DISCUSSION**

For locally advanced carcinoma cervix radiotherapy is the main modality of treatment and intracavitary brachytherapy is an essential part of it. In recent years, owing to the obvious physical advantages of shortened treatment time and better geometric placement HDR brachytherapy has gained popularity. No clear consensus of the appropriate number of fractions or appropriate dose per fraction has been reached. Various fractionation schemes have been used experimentally in search of the optimal technique. The number of fractions has varied from as low as 1 to as many as 16. The dose per fraction to point A has varied from 3 to 17 Gy/fraction [7-9].

Our present study was done using the HDR Microselectron with an Iridium 192 source and the HDR Microselectron Nucleotron applicator. We used a dose of 9 Gy/fraction of 2 fractions in Arm A and 3 fraction of 7 Gy/fraction in Arm B. The effects and toxicities were observed during and upto three years after completion of treatment. Both clinical examination and radiologic study (USG of W/A, CT scan of W/A) was done to see the presence of any microscopic residual disease or recurrence. Complete remission was observed in 90% of patients in arm A and it was 86% in arm B. The overall complete response was 88% at 6 month after completion of treatment. Statistical analysis revealed there was no significant difference between two arms. at 3 years follow up, complete response was 75% in both arms with 77% for arm A and 73% for arm B and p value was not significant.

The most prevalent acute toxicities in both the arms were bladder and rectum related toxicities, skin reaction, and vaginal mucositis. In arm A total 18 patients (60%) developed grade I and grade II skin toxicities whereas in arm B 16 patients (53.33%) developed skin reaction. Vaginal mucositis was present in 12 patients (40%) in arm A and 10 patients (33.33%) in arm B. Regarding bladder and rectal toxicities 20 patients (65%) in arm A and 16 (53%) patients in arm B developed bladder toxicities. 19 (61% ) patients in arm A and 16 (53%) patients in arm B developed grade III or grade IV toxicity and there was no interruption of treatment due to toxicity. Although treatment related toxicities were slightly more in arm A and was managed well but it was not statistically significant (p value <0.05).

During follow up at 3 years, 3 (9%) patients in arm A and 2 (7%) patient in arm B developed grade II bladder toxicities and only 5 (16%) patients in arm a developed rectal grade II toxicities and 3 (10%) patients rectal toxicity in arm B.
In different studies it is effectively shown that in choosing the number HDR fraction and consequently the dose per fraction, it is the prescribed dose received by the critical organs that is important. If the critical organ receive a smaller percentage of the point A dose, we can use larger dose per fraction without increasing morbidity [8-10]. The advantage of using fewer fractions is patient convenience and improved patient compliance. Two fractions of 9 Gy brachytherapy can be completed in less time and less exposure than three fractions of 7 Gy. Reducing the risk of multiple exposures to anesthetic agents and minimizing the number of hospital attendance makes this schedule cost effective. This schedule also reduces the patient load in radiotherapy centers to some extent which is a major consideration in a developing country like ours where radiotherapy centers are overburdened with cancer patients.

**CONCLUSION**

HDR brachytherapy 2 fractions of 9 Gy after concurrent chemoradiotherapy is equally effective in comparison with the brachytherapy of 3 fractions of 7 Gy after concurrent chemoradiotherapy for the control of locally advanced carcinoma cervix but more convenient regarding time and cost.

**REFERENCE**

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 2015 Mar 1;136(5).
2. Cancer Registry Report, National Institute of Cancer Research and Hospital, Mohakhali, Dhaka, 2012-2014, pp 08.
3. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, Franceschi S. Global burden of human papillomavirus and related diseases. Vaccine. 2012 Nov 20; 30:F12-23.
4. Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D. Human Papillomavirus and Related Diseases in the World. Summary Report. ICO Information Centre on HPV and Cancer (HPV Information Centre) 2016. [Last accessed on 2016 Nov 24].
5. Colombo N, Carinelli S, Colombo A, Marini C, Rollo D, Sessa C, ESMO Guidelines Working Group. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2012 Oct 1;23(suppl_7):vii27-32.
6. Barrett A, Morris S, Dobbs J, Roques T. Practical radiotherapy planning. CRC Press; 2009 Jun 26.
7. Patel FD, Sharma SC, Negi PS, Ghoshal S, Gupta BD. Low dose rate vs. high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: a clinical trial. International Journal of Radiation Oncology* Biology* Physics. 1994 Jan 15;28(2):335-41.
8. Viswanathan AN, Beriwal S, Jennifer F, Demanes DJ, Gaffney D, Hansen J, Jones E, Kirisits C, Thomadsen B, Erickson B. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. Brachytherapy. 2012 Jan 1;11(1):47-52.
9. Patel FD, Rai B, Mallick I, Sharma SC. High-dose-rate brachytherapy in uterine cervical carcinoma. International Journal of Radiation Oncology* Biology* Physics. 2005 May 1;62(1):125-30.
10. Fowler JF. The Radiobiology of brachytherapy. Brachytherapy HDR and LDR. 1990:121-37.